The use of NMDA-receptor antagonists in the treatment of chronic pain.
about
The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridineMethadone treatment of chronic non-malignant pain and opioid dependence--a long-term follow-upAntinociceptive Activity of Borreria verticillata: In vivo and In silico Studies.Drug repositioning using in silico compound profiling.Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review.Intracisternal administration of NR2 subunit antagonists attenuates the nociceptive behavior and p-p38 MAPK expression produced by compression of the trigeminal nerve root.In vivo activation of the SK channel in the spinal cord reduces the NMDA receptor antagonist dose needed to produce antinociception in an inflammatory pain modelMAGnesium-oral supplementation to reduce PAin in patients with severe PERipheral arterial occlusive disease: the MAG-PAPER randomised clinical trial protocol.Decreased pain response in mice following cortex-specific knockout of the N-methyl-D-aspartate NR1 subunitPre-Emptive Analgesia with Ketamine for Relief of Postoperative Pain After Surgical Removal of Impacted Mandibular Third Molars.NR2B-selective conantokin peptide inhibitors of the NMDA receptor display enhanced antinociceptive properties compared to non-selective conantokins.Post-synaptic density-93 mediates tyrosine-phosphorylation of the N-methyl-D-aspartate receptors.Stem cell therapy for neuropathic pain treatment.Efficacy of intra-articular magnesium for postoperative analgesia in total hip arthroplasty.The evolving nature of neuropathic pain: individualizing treatment.NMDARs in neurological diseases: a potential therapeutic target.A Case-Based Approach to Integrating Opioid Pharmacokinetic and Pharmacodynamic Concepts in Cancer Pain Management.Preemptive perineural bupivacaine attenuates the maintenance of mechanical and cold allodynia in a rat spinal nerve ligation modelEffects of Dextromethorphan on reducing methadone dosage in opium addicts undergoing methadone maintenance therapy: A double blind randomized clinical trial.D-aspartate modulates nociceptive-specific neuron activity and pain threshold in inflammatory and neuropathic pain condition in mice.Leptin enhances NMDA-induced spinal excitation in rats: A functional link between adipocytokine and neuropathic pain.Epidural ketamine in post spinal cord injury-related chronic pain.Going beyond efficacy: strategies for cancer pain management.Selective suppression of late laryngeal adductor responses by N-methyl-D-aspartate receptor blockade in the cat.Two N-methyl-D-aspartate receptors in rat dorsal root ganglia with different subunit composition and localization.Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.Pharmacokinetics of amantadine in cats.Effect of amantadine on oxymorphone-induced thermal antinociception in cats.Methadone as a "Tumor Theralgesic" against Cancer.Variations of isovaline structure related to activity in the formalin foot assay in mice.Examination of clozapine and haloperidol in improving ketamine-induced deficits in an incremental repeated acquisition procedure in BALB/c mice.Effect of bucladesine, pentoxifylline, and H-89 as cyclic adenosine monophosphate analog, phosphodiesterase, and protein kinase A inhibitor on acute pain.Ketamine and problems with advanced palliative care in the community setting.
P2860
Q24648725-4F3A045E-7045-476A-AD9F-ADD84B919B02Q28257915-67E29C07-1815-4742-80F0-B06EB64242CDQ33710983-BF7BB436-20E8-4F69-9582-6B939DE9F716Q34172485-70BF948A-470F-466E-8E10-C40B2E08292EQ34237650-EE067AB9-EB91-457E-8E4D-C9721F5BB10CQ35069330-BB288FBC-7A89-4EBC-8A33-F629A639CF82Q35597017-21001FAF-720F-47CF-B4DF-C0275E123048Q36406213-61EBD25C-D9CC-48CE-A3DA-78AABFE9D1B4Q36897283-042B4EA1-A11B-46E8-A2E4-FD37E699A40EQ36913855-CEB5B754-4083-468D-AFF5-9AB84D8A8F53Q37052031-8B1EDD4A-D18A-493C-925A-65F70318884BQ37226670-D80326E4-6AF0-4DDF-8DEA-657A68437E3AQ37536064-F379DC98-4130-4A7F-A952-DFF9E4BB215DQ37700851-EC6D6870-FA2A-413E-B1BC-0DD993B0321DQ38097476-E61EA0F7-F8E6-4FF9-9FC0-61D23A6ADDD9Q38232734-D8592AB2-7AFB-4C56-8D00-6113341A6AC3Q38655206-A3D19C51-32FA-434D-8A3D-F67D615D59E8Q40457570-F1B77E88-0D6E-41F0-A363-F8A0E77B69CEQ41817357-7EF88C68-AA04-4873-B45E-AB859D1D2463Q42150248-BA50BC7B-0DE4-4C9B-B4B9-85CC6D02B398Q42736961-43A24CDA-C70C-4987-9925-EE7C754D96F2Q42912573-AE734B81-2881-4F81-9B55-95ABF52A2DDBQ42976344-8DF4395D-32B1-4F0A-B84B-D7FA28A68E44Q43904755-EF98BADA-3AD1-4FC0-859B-A9808D10CDF0Q43959884-887B0C91-7FF4-4DBD-9E8B-FF5CFADE8298Q44571965-878A143C-9572-40BC-BC79-5129C0A5ECA6Q46076083-88A2A60B-7D25-4A41-8A2B-3C0F1DB76512Q46699417-AE862378-ED83-4906-87C5-3A165C7D4EBCQ47150971-1A3A1A26-5655-4180-AF41-FBE551BEAA58Q47304491-6076772F-2B3A-47F0-A0FA-6E720447FB8CQ47633556-780427E6-AA75-46BD-9A92-AEB232DE5466Q48154251-AF95CD77-6895-4A23-B14A-DC86A7FA3F15Q49161440-59BD408B-574E-47EE-B532-D7869E7090C1
P2860
The use of NMDA-receptor antagonists in the treatment of chronic pain.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The use of NMDA-receptor antagonists in the treatment of chronic pain.
@ast
The use of NMDA-receptor antagonists in the treatment of chronic pain.
@en
type
label
The use of NMDA-receptor antagonists in the treatment of chronic pain.
@ast
The use of NMDA-receptor antagonists in the treatment of chronic pain.
@en
prefLabel
The use of NMDA-receptor antagonists in the treatment of chronic pain.
@ast
The use of NMDA-receptor antagonists in the treatment of chronic pain.
@en
P1476
The use of NMDA-receptor antagonists in the treatment of chronic pain.
@en
P2093
P356
10.1097/00002508-200006001-00013
P407
P433
P577
2000-06-01T00:00:00Z